Royal College of Physicians and Surgeons of Canada

Dr. Verna Yiu appointed to EPCOR Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, MedlinePlus, Faculty, Royal College of Physicians and Surgeons of Canada, Health, Surgeon, University, AB, Alberta Health Services, Stollery Children's Hospital, EPCOR, Royal college, Medicine, Physician, Executive, Teaching, Public, Nephrology, Patient, Hospital, International Pediatric Nephrology Association, Pediatrics, Nursing

EDMONTON, AB, Nov. 1, 2023 /CNW/ - EPCOR Utilities Inc. (EPCOR) is pleased to announce the appointment of Dr. Verna Yiu to its Board of Directors.

Key Points: 
  • EDMONTON, AB, Nov. 1, 2023 /CNW/ - EPCOR Utilities Inc. (EPCOR) is pleased to announce the appointment of Dr. Verna Yiu to its Board of Directors.
  • "Dr. Yiu is highly recognized for her dedication and leadership in the fields of medicine and academia, as well as for her commitment to advancing the health and outlook of the patients in her care and the communities she serves," said Janice G. Rennie, EPCOR Board Chair.
  • We are fortunate and pleased to welcome her to our Board."
  • In addition to previous faculty leadership roles at the University of Alberta, Dr. Yiu served as the Executive Vice-President and Chief Medical Officer (2012-2016) and then as the President and CEO (2016-2022) of Alberta Health Services.

The Inner Circle Acknowledges, Joey Kevin Grochmal as a Pinnacle Life Member for his contributions to the Medical and Educational Fields

Retrieved on: 
Monday, August 21, 2023
Faculty, Royal college, University, Education, Health, Tetraplegia, Baylor College of Medicine, Stroke, Neoplasm, Medical college, Physician, Spinal cord, Infection, University of Alberta Faculty of Medicine and Dentistry, Baylor University, Spine, Head, Rehabilitation, Brain, Mentorship, Multimedia, Sympathetic nervous system, Disorder, Assistant, Inner circle, Science, SUNY Downstate Health Sciences University, Congress of Neurological Surgeons, Royal College of Physicians and Surgeons of Canada, American Association of Neurological Surgeons, Master of Science, Nervous system, Medical College of Wisconsin, Surgeon, Diagnosis, Knowledge, Society, Nursing, Dentistry, Medicine, Neuroscience, MD, Neurosurgery

HOUSTON, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joey Kevin Grochmal is acknowledged as a Pinnacle Life Member for his contributions to the Medical and Educational Fields.

Key Points: 
  • HOUSTON, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joey Kevin Grochmal is acknowledged as a Pinnacle Life Member for his contributions to the Medical and Educational Fields.
  • Dr. Grochmal pursued higher education at the University of Alberta in Canada where he received a Bachelor of Science degree in Neuroscience.
  • The doctor capped his scholarship by finishing a fellowship in spine surgery at the Medical College of Wisconsin in 2018.
  • Dr. Grochmal is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPSC).

World Renowned Biomedical Professor Jonathan Lakey Joins CancerVAX Board of Advisors

Retrieved on: 
Thursday, July 27, 2023
Meritorious Service Medal (China), BS, Radiation, University, Royal college, Diabetes, Meritorious Service Medal, Physician, Edmonton protocol, Enzyme, University of California, Irvine, Cancer, Research, Central Waqf Council, Doctor of Philosophy, Biomedical engineering, MS, Patient, Organ transplantation, Surgeon, B cell, Transplant, Royal College of Physicians and Surgeons of Canada, Disease, Dentistry, Science, LEHI

Dr. Lakey graduated from the University of Alberta with a BS, MS and PhD and received post-doctoral training in Indianapolis and Seattle.

Key Points: 
  • Dr. Lakey graduated from the University of Alberta with a BS, MS and PhD and received post-doctoral training in Indianapolis and Seattle.
  • Dr. Lakey is currently the Professor of Surgery and Biomedical Engineering and the Director of the Clinical Islet Program at University of California Irvine.
  • CancerVAX CEO Ryan Davies said, “We are honored to have Dr. Lakey join our Board of Advisors.
  • This is a noble cause and I am honored to have a part in the exciting work CancerVAX is doing”, said Dr. Lakey.

ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

Retrieved on: 
Monday, July 17, 2023
Memorial University of Newfoundland, Medical Affairs Bureau, Commercialization, Specialization, University, Royal college, Chronic kidney disease, Clinical associates, Physician, Framingham Heart Study, Department of Medicine – University of Pamplona, Health, Medicine, BD (company), Boston University, Business administration, Nephrology, Royal College of Physicians and Surgeons of Canada, Patient, Internal medicine, Baxter International, Surgeon, CVS Health, CKD, Medication, Kellogg School of Management, Pharmaceutical industry, Nursing, MD, Northwestern University

WINSTON-SALEM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization. Dr. Culleton, who will report to Chief Executive Officer Tim Bertram, joins ProKidney after more than two decades in industry and academia with a primary focus on kidney health.

Key Points: 
  • WINSTON-SALEM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization.
  • Tim Bertram, Chief Executive Officer of ProKidney, said: “I am thrilled to welcome Bruce to the ProKidney team.
  • Before joining CVS Health, he was Vice President, Global Clinical Development and World Wide Vice President, Medical Affairs, Medication and Procedural Solutions at Becton Dickinson; and previously Vice President, Renal Therapeutic Area at Baxter Healthcare.
  • Dr. Culleton added, “With Phase 3 clinical development well underway and initial interim data expected in late 2024, ProKidney is rapidly approaching an important inflection point.

Dr. Michele L. Ramien takes the helm as President of the Canadian Dermatology Association

Retrieved on: 
Monday, June 19, 2023
Royal college, University, Physician, Toronto, Pediatric Dermatology, Boston, St George Hospital, Mumbai, University of Ottawa Heart Institute, Certification, CDA, CHU, American Board of Commissioners for Foreign Missions, Royal College of Physicians and Surgeons of Canada, American Board of Dermatology, Hospital, Surgeon, McGill University, Nursing, Dermatology

OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is proud to announce the appointment of Dr. Michele L. Ramien as CDA President, effective June 16, 2023.

Key Points: 
  • OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is proud to announce the appointment of Dr. Michele L. Ramien as CDA President, effective June 16, 2023.
  • Dr. Ramien plans to advocate for, protect, and support the interests of Certified Dermatologists and the specialty of dermatology during her appointment as President.
  • Dr. Ramien brings strategic leadership, clinical expertise, and a growth-oriented mindset to the CDA, and has held previous positions as President Elect and Vice-President of the association.
  • The CDA welcomes Dr. Ramien as President, Canadian Dermatology Association for a one-year term.

Walmart Executive Joins GS1 US Board of Governors

Retrieved on: 
Thursday, May 11, 2023
The Coca-Cola Company, GS1, Topco, University, Club, Panzer corps, Sam's Club, Sysco, Sam, Information technology, Dot Foods, Physician, Wegmans, Royal College of Physicians and Surgeons of Canada, Procter & Gamble, EBay, PepsiCo, Dr. B. R. Ambedkar University Delhi, Organization, Engineering, Surgeon, Massachusetts Institute of Technology, Golden State Foods, The J.M. Smucker Company, GS1 US, Automation, Management, Online shopping, Walmart

EWING, N.J., May 11, 2023 /PRNewswire/ -- GS1 US has elected Bala Prasanna, vice president, store automation & innovation, Walmart, to join the GS1 US Board of Governors. Prasanna joins an accomplished cross-industry group of leaders who help guide the GS1 US strategy to drive greater adoption and use of GS1 Standards in the healthcare, apparel, general merchandise, retail grocery and foodservice sectors.

Key Points: 
  • EWING, N.J., May 11, 2023 /PRNewswire/ -- GS1 US has elected Bala Prasanna, vice president, store automation & innovation, Walmart, to join the GS1 US Board of Governors.
  • Prasanna joins an accomplished cross-industry group of leaders who help guide the GS1 US strategy to drive greater adoption and use of GS1 Standards in the healthcare, apparel, general merchandise, retail grocery and foodservice sectors.
  • In his current role, Prasanna leads a team that supports automation and innovation for US Walmart stores.
  • The GS1 US Board of Governors comprises executives from leading organizations including: Amazon; The Coca-Cola Company; Dot Foods, Inc.; eBay, Inc.; Golden State Foods; Google; The J.M.

LifeLabs Promotes Dr. Cathy Ross to Vice President of Medical and Quality Affairs, Driving Growth and Quality Healthcare Services Nationwide

Retrieved on: 
Wednesday, May 3, 2023
Abstract, Medicine, Royal college, Master of Science in Quality Management and Analytics, Cancer Care Ontario, Schulich School of Medicine & Dentistry, Safety, Physician, Business, CFB Toronto, Anatomical pathology, Quality, Royal College of Physicians and Surgeons of Canada, McMaster University, Pathology, Surgeon, Master, Quality assurance, Growth, Schulich School of Business, Hospital Insurance and Diagnostic Services Act, Patient safety, Complex, Medical device, Management, Science, List of pathologists

Dr. Ross's appointment marks an exciting new chapter in LifeLabs' growth story and underscores its commitment to building strong relationships and delivering high-quality healthcare services.

Key Points: 
  • Dr. Ross's appointment marks an exciting new chapter in LifeLabs' growth story and underscores its commitment to building strong relationships and delivering high-quality healthcare services.
  • "We are thrilled to have Dr. Cathy Ross leading our Med-Sci and Quality teams," said Charles Brown, CEO of LifeLabs.
  • "During her time with LifeLabs, Dr. Ross has built trusted relationships internally and externally and clearly understands LifeLabs' customers' needs.
  • As Vice President of Medical and Quality Affairs, Dr. Ross will oversee LifeLabs' Medical Science and Quality teams nationwide, playing a critical role in its operations and supporting LifeLabs' strategic objectives.

Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT

Retrieved on: 
Friday, April 14, 2023
Cream, Communication, Royal college, American Academy of Dermatology, BSA, College of Physicians and Surgeons of Ontario, JAK, Physician, Cancer, Pharmacokinetics, American Academy, Atopic dermatitis, Phase 2 (graffiti artist), Liu Minghui, Șaeș, Alopecia areata, Incidence, IGA, Royal College of Physicians and Surgeons of Canada, Surgeon, Prurigo nodularis, Vitiligo, AD, FDA, IND, Safety, Body surface area, Vaccine, Pharmaceutical industry, EASI

The study assessed safety, tolerability, pharmacokinetics (PK) and efficacy of two strengths of MH004 Cream.

Key Points: 
  • The study assessed safety, tolerability, pharmacokinetics (PK) and efficacy of two strengths of MH004 Cream.
  • "MH004 Cream is a topical cream containing a JAK inhibitor that was designed with Minghui's proprietary technology and formulation.
  • Based on the current phase 2 results, we plan to further pursue the development of MH004 Cream in atopic dermatitis as well as other dermatological diseases."
  • On April 1, the company received FDA IND approval for AD Phase 3 MRCTs after successful FDA communication and IND submission.

Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage

Retrieved on: 
Tuesday, April 4, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Vaccine, Inflammation, Faculty, Lupus, Royal college, LV, University, Physician, Royal College of Physicians and Surgeons of Canada, MedImmune, Manchester school, SLE, CMO, AAV, AstraZeneca, Disorder, Medication, Anifrolumab, M.D, Patient, Rocket, Hematology, Growth, Rare, Cardiology, Rest, News, Pharmaceutical medicine, Disease, Pharmaceutical industry, Medical device

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced expansion of its leadership team to support its growing and industry-leading pipeline of AAV and LV gene therapy assets and evolution towards commercial stage.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced expansion of its leadership team to support its growing and industry-leading pipeline of AAV and LV gene therapy assets and evolution towards commercial stage.
  • “Today’s news represents another exciting and important step forward in our leadership team as we make meaningful strides in our evolution towards commercial stage, adding deep late-stage development expertise and commercial experience to our team along with intensified focus on applying our technologies and successes to date across our pipeline,” said Gaurav Shah, M.D, Chief Executive Officer, Rocket Pharma.
  • “Jonathan’s exceptional scientific and clinical thought leadership will help unlock the full potential of gene therapy platforms for our pipeline and help advance the industry at large.
  • As Chief Gene Therapy Officer, Dr. Schwartz will oversee research, deepen relationships with external collaborators, and offer a pointed focus on clinical strategy and pipeline expansion.

Leading Diabetes Researcher Speaks on his Groundbreaking ‘Edmonton Protocol’ with CancerVAX CEO Ryan Davies

Retrieved on: 
Wednesday, March 22, 2023
Edmonton protocol, University of Alberta, Royal college, University, Diabetes, Doctor of Philosophy, Physician, Cancer, Edmonton, CancerVax, Research, Biomedical engineering, Transplant, Biomedicine, Patient, Surgeon, Governor, University of California, Irvine Medical Center, Royal College of Physicians and Surgeons of Canada, Dentistry, LEHI

LEHI, Utah, March 22, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that CEO Ryan Davies spoke with world-renown diabetes researcher Dr. Jonathan Lakey.

Key Points: 
  • LEHI, Utah, March 22, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that CEO Ryan Davies spoke with world-renown diabetes researcher Dr. Jonathan Lakey.
  • Specifically, Dr. Lakey’s Edmonton Protocol involves a procedure in which pancreatic beta-islet cells are transplanted in type I diabetes mellitus patients.
  • “Dr.
  • Lakey is an incredibly talented individual,” CancerVAX CEO Ryan Davies said, “His work on the Edmonton Protocol in addition to his hundreds of contributions to scientific research are incredibly important for helping type I diabetes patients.”
    For more information about CancerVax, please visit http://www.cancervax.com/ .